SCHEMBL18039003

SCHEMBL18039003

O=C(Cn1cc(S(=O)(=O)N2CCCC2)ccc1=O)c1ccc(-c2ccc(-c3ccc4ccccc4c3)cc2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MCOLN3 Q8TDD5 2/20 0.49
▸ TSHR P16473 1/20 0.49
▸ L3MBTL1 Q9Y468 2/20 0.48
▸ MEN1 O00255 2/20 0.46
▸ KMT2A Q03164 2/20 0.46
▸ MKNK1 Q9BUB5 1/20 0.44
▸ MKNK2 Q9HBH9 1/20 0.44
▸ PKM P14618 5/20 0.43
▸ ALDH1A1 P00352 2/20 0.43
▸ LMNA P02545 2/20 0.43
▸ SMN1; SMN2 Q16637 2/20 0.43
▸ POLB P06746 1/20 0.43
▸ NPSR1 Q6W5P4 1/20 0.43
▸ GAA P10253 2/20 0.43
▸ MAPT P10636 1/20 0.43
▸ AGTR1 P30556 1/20 0.42
▸ KAT6A Q92794 1/20 0.42
▸ RAB9A P51151 1/20 0.42
▸ HTT P42858 1/20 0.42
▸ HPGD P15428 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18038987 1.00 MCOLN3 (0.49) MCOLN3TSHRL3MBTL1MEN1KMT2A
SCHEMBL18038976 0.93 L3MBTL1 (0.48) MCOLN3TSHRL3MBTL1MEN1KMT2A
SCHEMBL18038965 0.90 L3MBTL1 (0.52) L3MBTL1MKNK1MKNK2PKMALDH1A1
SCHEMBL18038959 0.90 L3MBTL1 (0.56) L3MBTL1MEN1KMT2APKMALDH1A1
SCHEMBL18038954 0.90 L3MBTL1 (0.56) L3MBTL1MEN1KMT2APKMALDH1A1
SCHEMBL18038989 0.90 L3MBTL1 (0.56) L3MBTL1MEN1KMT2APKMALDH1A1
SCHEMBL18038953 0.89 L3MBTL1 (0.53) L3MBTL1MEN1KMT2APKMALDH1A1
SCHEMBL22050482 0.88 L3MBTL1 (0.45) TSHRL3MBTL1MEN1KMT2AMKNK1
SCHEMBL22050817 0.88 L3MBTL1 (0.45) TSHRL3MBTL1PKMALDH1A1LMNA
SCHEMBL18038951 0.86 L3MBTL1 (0.52) TSHRL3MBTL1MKNK1MKNK2PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11311523-B2 Pyridinone compound and use thereof KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) 2022-04-26 — — US disclosed
EP-3692992-A1 METHOD OF SCREENING DOCK1-SELECTIVE INHIBITORS FOR CANCER TREATMENT Kyushu University National University Corporation (JP) 2020-08-12 — — EP disclosed
EP-3263133-B1 PYRIDINONE COMPOUND AND USE THEREOF UNIV KYUSHU NAT UNIV CORP (JP) 2020-04-01 — — EP disclosed
US-20200061039-A1 PYRIDINONE COMPOUND AND USE THEREOF KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) 2020-02-27 — — US disclosed
US-10406141-B2 Pyridinone compound and use thereof KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) 2019-09-10 — — US disclosed
US-20180028515-A1 PYRIDINONE COMPOUND AND USE THEREOF KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (JP) 2018-02-01 — — US disclosed
EP-3263133-A1 PYRIDINONE COMPOUND AND USE THEREOF Kyushu University, National University Corporation (JP) 2018-01-03 — — EP disclosed
WO-2016136985-A1 PYRIDINONE COMPOUND AND USE THEREOF 国立大学法人九州大学 2016-09-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180028515-A1 PYRIDINONE COMPOUND AND USE THEREOF DOCK5, DOCK2, CIB1 MCOLN3 3546/4885TSHR 4787/4885L3MBTL1 2983/4885
US-20200061039-A1 PYRIDINONE COMPOUND AND USE THEREOF DOCK5, DOCK2, CIB1 MCOLN3 3621/4885TSHR 4793/4885L3MBTL1 2940/4885
US-10406141-B2 Pyridinone compound and use thereof DOCK5, DOCK2, CIB1 MCOLN3 3546/4885TSHR 4787/4885L3MBTL1 2983/4885
US-11311523-B2 Pyridinone compound and use thereof DOCK5, DOCK2, CIB1 MCOLN3 3621/4885TSHR 4793/4885L3MBTL1 2940/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback